| Editor's Note: Fierce PM Tracker won't be delivered this Thursday and Friday in observance of the federal July 4th holiday. Enjoy the time off, and we'll be back in your inbox Monday, July 8. |
|
Cell therapy developers face many challenges as they transition from benchtop to bedside. Here we examine when and how to consider transitioning from research-use-only to animal-free (AF) and GMP critical reagents. Download now.
|
|
Today’s Big NewsJul 3, 2024 |
|
September 25-27, 2024 | Philadelphia, PA Join the Fierce Clinical Summit, the premier event for clinical research and trial management. Explore topics in Clinical Operations, Quality, and DCT & Technology. Learn, network, and connect with peers to advance industry standards and innovations in clinical trials. Secure your pass today!
|
|
| By Conor Hale Roche has filed a lawsuit against Stanford University and its spinout Foresight Diagnostics, saying the young cancer test developer was built upon trade secrets it acquired for detecting tumor DNA in the bloodstream. |
|
|
|
By Kevin Dunleavy After more than a decade with no treatment advances for chronic obstructive pulmonary disease (COPD), two have been approved by regulators on either side of the Atlantic within a week. July 3, the European Medicines Agency signed off on Regeneron and Sanofi’s anti-inflammatory blockbuster Dupixent to treat COPD, which restricts airflow from the lungs and leaves patients struggling to breathe. |
By Nick Paul Taylor GSK is paying 400 million euros upfront for full rights to CureVac’s mRNA vaccines against influenza and COVID-19. The mRNA specialist shared news of the deal alongside a restructuring that will put 30% of its employees out of work and extend its cash runway into 2028. |
By Nick Paul Taylor Inovio has changed its chief commercial officer ahead of the planned launch of its first DNA medicine, putting the Merck veteran Steven Egge in charge of leading the strategy and operations. |
|
Dive into the cutting-edge world of recombinant antibody engineering, from optimizing your antibody plasmid to antibody maturation and humanization. Explore innovative techniques and strategies that enhance antibody efficacy, paving the way for breakthroughs in therapeutic development. Download now.
|
|
By Angus Liu The world’s first injectable immune checkpoint inhibitor likely won’t make it to the U.S. anytime soon, after the China-approved drug flunked a pivotal trial in a rare cancer, forcing its stateside developer Tracon to explore strategic alternatives. |
By James Waldron Beacon Therapeutics has raised a $170 million series B, which the U.K.-based gene therapy biotech will use to push its eye disease candidates through clinical trials. |
By Conor Hale The company’s PancreasPak builds upon its previous smart cooler offerings for shepherding hearts, lungs and livers. |
By Zoey Becker The drugmaker will supply its anthrax vaccine Cyfendus, its smallpox vaccine and two other drugs to help bolster the U.S. government's medical countermeasures stockpile. |
By James Waldron Radiopharmaceutical company Pentixapharm is picking up fellow Germany-based Glycotope's discovery unit for an undisclosed sum in order to double its pipeline courtesy of a portfolio of preclinical cancer antibodies. |
Fierce podcastsDon’t miss an episode |
| | In today’s episode of "The Top Line," Fierce Biotech’s Annalee Armstrong and James Waldron discuss what they think are the best and smartest biopharma acquisitions in recent years. |
|
|---|
|
|
|
Download this resource to accelerate your oncology clinical trials, optimize patient enrollment, and monitor minimal residual disease and molecular response effectively. Explore how this tissue-free, methylation-based technology enhances circulating tumor DNA (ctDNA) detection, enriching trial populations and evaluating therapy responses faster than tissue assays.
|
|
| WhitepaperIn this white paper, Lonza experts delve into the common challenges encountered by ADC developers. They explore new drug product capabilities in relation to cytotoxic drug development and manufacturing, therefore fully completing Lonza’s integrated ADC offering. Further, they discuss how this end-to-end approach can significantly accelerate the timeline to investigational new drug filing and beyond. Read this white paper to learn more. Sponsored by: Lonza |
| WhitepaperThe definitive report on the state of our industry. Readers will gain an understanding of key indicators to monitor, future predictions, and guidance for investors and founders navigating the therapeutic enabling tools and services, healthtech and techbio sectors through 2024 and beyond. Sponsored by: AVANT BIO |
| WhitepaperIn a complex industry like biopharma, being a “Best Practice Organization” (BPO) is essential to success. But what is a BPO & how do you build one? This eBook provides the answers. Sponsored by: Blue Matter, strategic consultants in the life sciences |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
